Cargando…

Biotechnological approach for systemic delivery of membrane Receptor Activator of NF-κB Ligand (RANKL) active domain into the circulation

Deficiency of Receptor Activator of NF-κB Ligand (RANKL) prevents osteoclast formation causing osteopetrosis. RANKL is a membrane-bound protein cleaved into active soluble (s)RANKL by metalloproteinase 14 (MMP14). We created a bio-device that harbors primary osteoblasts, cultured on 3D hydroxyapatit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cappariello, Alfredo, Paone, Riccardo, Maurizi, Antonio, Capulli, Mattia, Rucci, Nadia, Muraca, Maurizio, Teti, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337851/ https://www.ncbi.nlm.nih.gov/pubmed/25678116 http://dx.doi.org/10.1016/j.biomaterials.2014.12.033

Ejemplares similares

Circulating Extracellular Vesicles Express Receptor Activator of Nuclear Factor κB Ligand and Other Molecules Informative of the Bone Metabolic Status of Mouse Models of Experimentally Induced Osteoporosis
por: Cappariello, Alfredo, et al.
Publicado: (2022)

Notch2 pathway mediates breast cancer cellular dormancy and mobilisation in bone and contributes to haematopoietic stem cell mimicry
por: Capulli, Mattia, et al.
Publicado: (2019)

Effective Small Interfering RNA Therapy to Treat CLCN7-dependent Autosomal Dominant Osteopetrosis Type 2
por: Capulli, Mattia, et al.
Publicado: (2015)

Interleukin-1β, lipocalin 2 and nitric oxide synthase 2 are mechano-responsive mediators of mouse and human endothelial cell-osteoblast crosstalk
por: Veeriah, Vimal, et al.
Publicado: (2016)

The glycosaminoglycan-binding domain of PRELP acts as a cell type–specific NF-κB inhibitor that impairs osteoclastogenesis
por: Rucci, Nadia, et al.
Publicado: (2009)

The Role of Extracellular Vesicles (EVs) in the Epigenetic Regulation of Bone Metabolism and Osteoporosis
por: Muraca, Maurizio, et al.
Publicado: (2020)

Tumour-Derived Extracellular Vesicles (EVs): A Dangerous “Message in A Bottle” for Bone
por: Cappariello, Alfredo, et al.
Publicado: (2019)

Extracellular Vesicles in Bone Tumors: How to Seed in the Surroundings Molecular Information for Malignant Transformation and Progression
por: Cappariello, Alfredo, et al.
Publicado: (2021)

Lipocalin 2 increases after high‐intensity exercise in humans and influences muscle gene expression and differentiation in mice
por: Ponzetti, Marco, et al.
Publicado: (2021)

Extra-skeletal manifestations in mice affected by Clcn7-dependent autosomal dominant osteopetrosis type 2 clinical and therapeutic implications
por: Maurizi, Antonio, et al.
Publicado: (2019)

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
por: Widschwendter, Martin, et al.
Publicado: (2015)

Resveratrol-mediated SIRT-1 Interactions with p300 Modulate Receptor Activator of NF-κB Ligand (RANKL) Activation of NF-κB Signaling and Inhibit Osteoclastogenesis in Bone-derived Cells
por: Shakibaei, Mehdi, et al.
Publicado: (2011)

TRAF6 Autoubiquitination-Independent Activation of the NFκB and MAPK Pathways in Response to IL-1 and RANKL
por: Walsh, Matthew C., et al.
Publicado: (2008)

Selective inhibition of receptor activator of NF-κB ligand (RANKL) in hematopoietic cells improves outcome after experimental myocardial infarction
por: Slavic, Svetlana, et al.
Publicado: (2018)

In Silico Discovery of Plant-Origin Natural Product Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL)
por: Melagraki, Georgia, et al.
Publicado: (2018)

Non-conventional role of haemoglobin beta in breast malignancy
por: Ponzetti, Marco, et al.
Publicado: (2017)

Lipocalin 2 Influences Bone and Muscle Phenotype in the MDX Mouse Model of Duchenne Muscular Dystrophy
por: Ponzetti, Marco, et al.
Publicado: (2022)

Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities
por: Joung, Youn Hee, et al.
Publicado: (2016)

Lipocalin 2 serum levels correlate with age and bone turnover biomarkers in healthy subjects but not in postmenopausal osteoporotic women
por: Maurizi, Antonio, et al.
Publicado: (2021)

Testing the Cre-mediated genetic switch for the generation of conditional knock-in mice
por: Capulli, Mattia, et al.
Publicado: (2019)

Nepetin inhibits osteoclastogenesis by inhibiting RANKL‐induced activation of NF‐κB and MAPK signalling pathway, and autophagy
por: Chu, Binxiang, et al.
Publicado: (2020)

Involvement of Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-induced Incomplete Cytokinesis in the Polyploidization of Osteoclasts
por: Takegahara, Noriko, et al.
Publicado: (2016)

Structure-Based Discovery of Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-Induced Osteoclastogenesis Inhibitors
por: Rinotas, Vagelis, et al.
Publicado: (2023)

Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages
por: Jin, Gu, et al.
Publicado: (2018)

Aspirin inhibits osteoclastogenesis by suppressing the activation of NF-κB and MAPKs in RANKL-induced RAW264.7 cells
por: Zeng, Yan-Ping, et al.
Publicado: (2016)

FNDC4 Inhibits RANKL-Induced Osteoclast Formation by Suppressing NF-κB Activation and CXCL10 Expression
por: Lv, Zheng-tao, et al.
Publicado: (2018)

Aspirin inhibits RANKL-induced osteoclast differentiation in dendritic cells by suppressing NF-κB and NFATc1 activation
por: Wu, Lili, et al.
Publicado: (2019)

Tyloxapol inhibits RANKL-stimulated osteoclastogenesis and ovariectomized-induced bone loss by restraining NF-κB and MAPK activation
por: Guo, Wen, et al.
Publicado: (2021)

Maackiain dampens osteoclastogenesis via attenuating RANKL‐stimulated NF‐κB signalling pathway and NFATc1 activity
por: Liu, Yuhao, et al.
Publicado: (2020)

Cheminformatics-aided discovery of small-molecule Protein-Protein Interaction (PPI) dual inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL)
por: Melagraki, Georgia, et al.
Publicado: (2017)

Evaluation of Isoflavones as Bone Resorption Inhibitors upon Interactions with Receptor Activator of Nuclear Factor-κB Ligand (RANKL)
por: Zakłos-Szyda, Małgorzata, et al.
Publicado: (2020)

The Osteoclast in Bone Metastasis: Player and Target
por: Maurizi, Antonio, et al.
Publicado: (2018)

Receptor activator of NF-kappaB ligand (RANKL) and CD 31 expressions in chronic periodontitis patients before and after surgery
por: Friedmann, Anton, et al.
Publicado: (2014)

Calycosin Suppresses RANKL-Mediated Osteoclastogenesis through Inhibition of MAPKs and NF-κB
por: Quan, Gui-Hua, et al.
Publicado: (2015)

Natural Germacrane Sesquiterpenes Inhibit Osteoclast Formation, Bone Resorption, RANKL-Induced NF-κB Activation, and IκBα Degradation
por: Qin, Shengnan, et al.
Publicado: (2015)

TRAF Family Member-Associated NF-κB Activator (TANK) Induced by RANKL Negatively Regulates Osteoclasts Survival and Function
por: Wu, Mengrui, et al.
Publicado: (2012)

Amyloid β Peptide Enhances RANKL-Induced Osteoclast Activation through NF-κB, ERK, and Calcium Oscillation Signaling
por: Li, Shangfu, et al.
Publicado: (2016)

TNF-α and RANKL promote osteoclastogenesis by upregulating RANK via the NF-κB pathway
por: Luo, Gang, et al.
Publicado: (2018)

Isoliquiritigenin Derivatives Inhibit RANKL-Induced Osteoclastogenesis by Regulating p38 and NF-κB Activation in RAW 264.7 Cells
por: Jeong, Seongtae, et al.
Publicado: (2020)

The Effect of Osteoprotectin (OPG)/Receptor Activator of Nuclear Factor-κB Ligand (RANKL)/Receptor Activator of Nuclear Factor-κB (RANK) Gene Methylation on Aortic Valve Calcified
por: Luo, Wei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lkdkd2g18h57gi8vt9arvtrhkn